Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 22, 2014, Pages 9611-9614

  Wang, Bing ^a   He, Yu Jie ^a   Tian, Ying Xing ^a   Yang, Rui Ning ^a   Zhu, Yue Rong ^a   Qiu, Hong ^a  

^a The 81th Hospital of PLA   (China)

Author keywords

CEA; CYFRA21 1; Diagnosis; Hp; Lung cancer; NSE

Indexed keywords

EID: 84921459970     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.22.9611     Document Type: Article

References (15)

1. Asleh R, Ward J, Levy NS, et al (2014). Haptoglobin genotype-dependent differences in macrophage lysosomal oxidative injury. J Biol Chem, 23, 16313-25.
2. Bertaggia E, Scabia G, Dalise S, et al (2014). Haptoglobin is required to prevent oxidative stress and muscle atrophy. PLoS One, 9, 0100745.
3. Chih-Ho Lai, Nai-Wen Chang, Chin-Fen Lin, et al (2010). Proteomics-based identification of haptoglobin as a novel plasma biomarker in oral squamous cell carcinoma. Clinica Chimica Acta, 411, 984-91.
4. Ding Y, Xuan W, Chen C, et al (2014). Differences in carcinoembryonic antigen levels between colon and rectal cancer. Mol Clin Oncol, 2, 618-22.
5. Farooqui MS, Mittal A, Poudel B, et al (2012). Improved diagnostic accuracy of pancreatic diseases with a combination of various novel serum biomarkers. Asian Pac J Cancer Prev, 13, 2171-74.
6. Fujita K, Shimomura M, Uemura M, et al (2014). Serum fucosylated haptoglobin as a novel prognostic biomarker predicting high-Gleason prostate cancer. Prostate, 74, 1052-58.
7. Jessie K, Jayapalan JJ, Ong KC, et al (2013). Aberrant proteins in the saliva of patients with oral squamous cell carcinoma. Electrophoresis, 34, 2495-502.
8. Juan HF, Chen JH, Hsu WT, et al (2004). Identification of tumor-associated plasma biomarkers using proteomic techniques; from mouse to human. Proteomics, 4, 2766-75.
9. Kang SM, Sung HJ, Ahn JM, et al (2011). The Haptoglobin beta chain as a supportive biomarker for human lung cancers. Mol Biosyst, 7, 1167-75.
10. Langlois MR, Delanghe (1996). Biological and clinical significance of haptoglobin polymorphism in hunmans. Clin Chem, 42, 1589-600.
11. Lee KJ, Yi SW, Chung MJ, et al (2013). Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J, 54, 643-9.
12. Melamed-Frank M, Lache O, Enav B I, et al (2001). Structure-function analysis of the antioxidant properties of haptoglobin. Blood, 98, 3693-8.
13. Schneider J, Bitterlich N, Velcovsky H G, et al (2005). Fuzzy logicbased tumor-marker profiles improved sensitivity in the diagnosis of lung cancer. Proteomics, 5, 4581-8.
14. Tan W, Wang F, Guo D, et al (2014). High serum level of haptoglobin is associated with the response of 12 weeks methotrexate therapy in recent-onset rheumatoid arthritis patients. Int J Rheum Dis, 2014, 12380 [Epub ahead of print].
15. Zhu J, Lin Z, Wu J, et al (2014). Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res, 13, 2986-97.